Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P561.

Anti-TNFalpha drug level measurements in IBD patients

Authors:

M. Rekvig1, M. Gedde Dahl1, J. Bratlie1, N. Bolstad2, B. Moum3, J. Jahnsen4, K.E.A. Lundin1, 1Oslo University Hospital Rikshospitalet, Gastroenterology, Oslo, Norway, 2Oslo University Hospital Radiumhospitalet, Biochemistry, Oslo, Norway, 3Oslo University Hospital Ullevål, Gastroenterology, Oslo, Norway, 4Akershus University Hospital, Gastroenterology, Oslo, Norway

P561. Comparison of clinical characteristics of inflammatory bowel disease patients according to the age of diagnosis
Authors:

E.Y. Kim1, E.S. Kim2, K.B. Cho2, K.S. Park2, B.I. Jang3, K.O. Kim3, C.H. Yang4, 1Catholic University of Daegu School of Medicine, Internal Medicine, Daegu, South Korea, 2Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea, 3Yeungnam University College of Medicine, Internal Medicine, Daegu, South Korea, 4Dongguk University Hospital, Internal Medicine, Kyungju, South Korea

P561

Time course and clinical implications of development of binding and neutralizing antibodies against adalimumab in patients with inflammatory bowel disease

Authors:

C. Steenholdt*1, M.T. Frederiksen1, K. Bendtzen2, M.A. Ainsworth1, O.Ø. Thomsen1, J. Brynskov1

1Herlev Hospital, Dept of Gastroenterology, Herlev, Denmark, 2Rigshospitalet, University Hospital of Copenhagen, Institute for Inflammation Research, Copenhagen, Denmark

P562.

Anti-TNF alpha blocking agents as a first-line therapy for IBD-associated pyoderma gangrenosum

Authors:

M. Fortuna, R. Montanari, A. Geccherle, M. Chiaramonte, Sacro Cuore Don Calabria Negrar Hospital, Multispecialistic Centre for Recto-Perineal Diseases (IBD Unit), Department of Gastroenterology, Negrar (VR), Italy

P562. Comparing the efficacy of once-daily or twice-daily mesalazine dosing in the treatment of left-sided ulcerative colitis versus the overall MOTUS study population
Authors:

B. Flourié1, J. Kuyvenhoven2, C. Probert3, O. Dewit4, 1Centre Hospitalo-Universitaire Lyon-Sud, Department of Gastroenterology, Lyon, France, 2Kennemer Gasthuis, Department of Gastroenterology and Hepatology, Haarlem, Netherlands, 3University of Liverpool, Liverpool, United Kingdom, 4UCL Saint Luc, Brussels, Belgium

P562

Clinical outcomes of surgery versus endoscopic balloon dilatation for stricturing Crohn's disease

Authors:

T. Greener*1, U. Kopylov1, R. Shapiro2, E. Klang3, N. Rozendorn3, R. Eliakim1, M.M. Amitai3, S. Ben-Horin1

1Chaim Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 2Chaim Sheba Medical Center, Surgery B, Tel Hashomer , Israel, 3Chaim Sheba Medical Center, Radiology , Tel Hashomer, Israel

P563.

Anti-TNF therapy reduces ionising radiation exposure in patients with ulcerative colitis

Authors:

D. Aggarwal, J.K. Limdi, The Pennine Acute Hospitals NHS Trust, Department of Gastroenterology, Manchester, United Kingdom

P563. Clinical response and quality of life in patients with Crohn's disease treated with adalimumab in routine clinical practice
Authors:

D. Ceballos1, F. Muñoz2, C. Saro3, C. De la Coba3, M.D. Aguilar4, P. Lazaro4, 1Dr. Negrín Hospital, Spain, 2Hospital de León, León, Spain, 3Cabueñes Hospital, Spain, 4TAISS, Madrid, Spain

P563

Vedolizumab exposure in pregnancy: Outcomes from clinical studies in inflammatory bowel disease

Authors:

M. Dubinsky*1, U. Mahadevan2, S. Vermeire3, B. Abhyankar4, K. Lasch5

1Mount Sinai Hospital, Pediatric Gastroenterology, New York, United States, 2University of California San Francisco, Clinical Medicine, CA, United States, 3University Hospital Gasthuisberg, Gastroenterology, Leuven, Belgium, 4Takeda Global Research and Development Centre (Europe) Ltd., Clinical Science, London, United Kingdom, 5Takeda Pharmaceuticals International Inc., Medical Affairs, Deerfield, IL, United States

P564.

An innovative information technology tool to promote patient self-care – A web-based ‘IBD patient portal’

Authors:

M. Naghibi, M. Bettey, J.R.F. Cummings, University Hospital Southampton, Gastroenterology, Southampton, United Kingdom

P564. Clinical response, quality of life and work activity in patients with Crohn's disease treated with adalimumab in routine clinical practice
Authors:

C. Saro1, D. Ceballos2, F. Muñoz3, C. De la Coba1, M.D. Aguilar4, P. Lazaro4, 1Cabueñes Hospital, Spain, 2Dr. Negrín Hospital, Spain, 3Hospital de León, León, Spain, 4TAISS, Madrid, Spain

P564

Changes of fecal calprotectin concentrations after adalimumab induction therapy in patients with moderate-to-severe Crohn's disease

Authors:

K.-M. Lee*1, S.-K. Yang2, H.J. Kim3, Y.H. Kim4, G.A. Song5, J.P. Im6, B.I. Jang7, S.-A. Jung8, Y.T. Jeen9, J.S. Koo9, J.H. Cheon10, S.J. Park10, Y.J. Kim11, C.S. Eun12, T.-O. Kim13

1St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Internal Medicine, Suwon, Gyenggi-do, South Korea, 2University of Ulsan College of Medicine, Asan Medical Center, Gastroenterology, Seoul, South Korea, 3Kyung Hee University School of Medicine, Internal medicine, Seoul, South Korea, 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Gastroenterology, Seoul, Korea, Republic of, 5Pusan National University School of Medicine, Department of Internal Medicine, Busan, South Korea, 6Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea, Republic of, 7Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, Korea, Republic of, 8Ewha Womans University School of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of, 9Korea University College of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of, 10Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea, Republic of, 11Gachon University Gil Medical Center, Internal Medicine, Incheon, Korea, Republic of, 12Hanyang University Guri Hospital, Internal Medicine, Guri, Korea, Republic of, 13Haeundae Paik Hospital, Inje University College of Medicine, Department of Internal Medicine, Gastroenterology, Busan, Korea, Republic of

P565.

An experience of anti-TNF biosimilar, CT-P13 use: clinical efficacy, safety and interchangeability in inflammatory bowel disease; a pilot study

Authors:

H.W. Kang, Y.J. Lim, J.H. Kim, Y.-S. Kang, Dongguk University Ilsan Hospital, Department of Internal Medicine, Goyang, Korea, Republic of

P565. Clinically significant safety issues during long-term azathioprine use in patients with ulcerative colitis
Authors:

K. Katsanos1, V. Tsianos1, S. Zachariadou1, I. Vagias1, S. Liamas1, A. Tatsioni2, D. Sigounas1, I. Mitselos1, D. Christodoulou1, E. Tsianos1, for the NW Greece IBD Study Group, 1University of Ioannina, Ioannina, Greece, 2Department of Family Medicine University of Ioanninaand Tufts-New England Medical Center Evidence-Based Practice Center, Institute for Clinical Research and Health Policy Studies, Boston, USA

P565

The Increased Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients is not Related To Inflammatory Load

Authors:

Y. Erzin1, N. Demir1, C. Cabuk1, F. Kantarci2, I. Hatemi*1, A.F. Celik1

1Istanbul University Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey, 2Istanbul University Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey

P566.

A matrix-based prediction model for primary response to infliximab in Crohn's disease patients

Authors:

T. Billiet1, M. de Bruyn1, K. Claes1, V. Ballet2, X. Liu3, R. Kirkland3, K. Drake3, S. Lockton3, F. Princen3, S. Singh3, M. Ferrante2, G. Van Assche2, P. Rutgeerts2, I. Cleynen1, S. Vermeire2, 1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 2University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 3Prometheus Laboratories, Department of Research and Development, San Diego, United States

P566. Clinical course of severe colitis; a comparison between Crohn's colitis and ulcerative colitis
Authors:

E. Sinagra1, F. Mocciaro1, A. Scalisi1, V. Criscuoli1, A. Orlando1, M. Olivo1, M. Giunta1, M. Cottone1, 1Ospedali Riuniti Villa Sofia – Cervello, DIBIMIS, Division of Internal Medicine, Palermo, Italy

P566

Efficacy and safety of vedolizumab with advancing age in patients with ulcerative colitis: Results from the GEMINI 1 study

Authors:

V. Yajnik*1, N. Khan2, M. Dubinsky3, J. Axler4, A. Green5, B. Abhyankar6, K. Lasch7

1Massachusetts General Hospital, Harvard Medical School, Gastroenterology, Boston, MA, United States, 2University of Pennsylvania, Perelman School of Medicine, Medicine, Philadelphia, Pennsylvania, United States, 3Mount Sinai Hospital, Pediatric Gastroenterology, New York, United States, 4Toronto Digestive Disease Associates, University of Toronto, Gastroenterology, Toronto, Canada, 5Takeda Global Research & Development Centre (Europe) Ltd., Statistics, London, United Kingdom, 6Takeda Global Research and Development Centre (Europe) Ltd., Clinical Science, London, United Kingdom, 7Takeda Pharmaceuticals International Inc., Medical Affairs, Deerfield, IL, United States

P567.

Allogeneic haematopoietic stem cell transplant (HSCT) for paediatric Crohn's disease: A case report

Authors:

S. Chadokufa1, B. Huggett1, M. Mamoun Elawad2, J. Kammermeier1, F. Kiparissi2, N. Shah2, 1Great Ormond Street Hospital, Paediatric Gastroemterology, London, United Kingdom, 2Great Ormond Street Hospital, Gastro, London, United Kingdom

P567. Budesonide induces clinical remission and improves quality of life in active collagenous colitis: results from the open-label induction phase of BUC-63/COC
Authors:

A. Münch1, J. Bohr2, C. Benoni3, M. Olesen3, Å. Öst4, H. Hjortswang1, P.M. Hellström5, L. Strandberg6, J. Björk7, E. Hertervig8, G. Lindberg7, A. Lapidus7, R. Löfberg7, S. Miehlke9, C. Kirsch10, P. Armerding11, O. Bonderup12, J. Stehlik13, R. Müller14, R. Greinwald14, C. Tysk15, M. Ström1, 1University Hospital, Gastroenterology, Linköping, Sweden, 2University Hospital, Gastroenterology, Örebro, Sweden, 3University Hospital, Gastroenterology, Malmö, Sweden, 4Medilab, Pathology, Stockholm, Sweden, 5University Hospital, Gastroenterology, Uppsala, Sweden, 6Regional hospital, Falun, Sweden, 7University Hospital, Stockholm, Sweden, 8University Hospital, Lund, Sweden, 9Center for Digestive Disease, Hamburg, Germany, 10University Hospital, Dresden, Germany, 11Priviate practice, Berlin, Germany, 12Regional hospital, Silkeborg, Denmark, 13Regional hospital, Usti nad Labem, Czech Republic, 14Falk Pharma, Freiburg, Germany, 15University Hospital, Gastroenterology, Örebro, Sweden